MUMBAI, India, June 24 -- Intellectual Property India has published a patent application (202617059677 A) filed by Medeze Treasury Pte. Ltd on May 11, 2026, for Composition Comprising Avenanthramide C For Inducing Differentiation Of Mesenchymal Stem Cells Into Chondrocytes And Method Of Using The Same.
Inventor includes Khemarangsan, Veerapol.
The application for the patent was published on June 12, 2026, under issue no. 24/2026.
Abstract: The present invention discloses an application of Avenanthramide C (Avn C) as an inducer of chondrocyte differentiation in Mesenchymal Stem Cells (MSCs), providing a promising approach for regenerative cartilage therapies. By employing Avn C treatments, MSCs exhibit enhanced chondrocyte differentiation with elevated expression of key specific chondrogenic extracellular matrix (ECM) factors, notably collagen type 2 (COL2A1). Moreover, a synergistic effect is observed when Avn C is used in combination with Chondroitin Sulfate (CS), resulting in the upregulation of the transcriptionally active state of SOX9, a crucial regulator of chondrogenesis. The disclosed invention demonstrates significant improvements in mRNA gene expressions (ACAN, LRP1, SOX9), cellular protein levels (COL2A1, SOX9, LRP1), and functional outcomes, as evidenced by the secretion of extracellular matrix proteins (FSTL-1, BGH3, CO1A1, CO1A2, and CO3A1).
Disclaimer: Curated by HT Syndication.
